Best ASX small-cap stocks to buy right now

All investors have a desire to capture the growth from upcoming multi-baggers and a few ASX small-caps are starting to show real progress while following the same footsteps that other great companies did while they were in their growth phase. Praemium (PPS), Amaero (3DA), Core Lithium (CXO) and Integral Diagnostics (IDX) stand out as the small-caps which have potential to become scalable and high margin businesses in future. These companies are reaching important milestones while constantly improving their operations and their business models have great intrinsic advantages along with improvement in financial as they scale. Below are the latest updates explaining why each one is becoming an attractive pick in today’s market.

Best ASX small-cap stocks

Praemium Limited (ASX: PPS) 

Amaero Limited (ASX: 3DA) 

Core Lithium Limited (ASX: CXO) 

Integral Diagnostics Limited (ASX: IDX) 

Praemium Limited (ASX: PPS) 

runs a fully integrated platform that lets advisers and wealth managers build both custody and non-custody solutions for clients.
Total Funds Under Administration (FUA) grew by 13% to around $67 billion in the September 2025 quarter which shows its solid and growing position.

Platform FUA jumped by 10% to $32 billion and net inflows came in at $667 million due to good demand across Spectrum, SMA and Powerwrap.
With growing inflows and FUA along with a business model with high switching costs, Praemium is positioning itself for another year of growth in FY26.

Amaero Limited (ASX: 3DA) 

is slowly turning into one of the most advanced players in the U.S defence and aerospace supply chain as it is moving out of the development phase and getting into commercial production now.
One of the biggest was the commissioning of its second EIGA Premium atomiser which has boosted its ability to make high-purity refractory and titanium alloy powders in a big way.

FY2025 revenue went up to around $3.8 million and this was helped by strong powder sales and more PM-HIP parts being produced.
A big milestone was the five-year exclusive supply deal with Velo3D and the whole contract is expected to bring in roughly $35 million over five years.

Core Lithium Limited (ASX: CXO) 

made big moves in the September quarter by pushing ahead with the restart study and setting up Finniss Lithium operation as a long-life, low-cost underground lithium project with a planned mine life of around 20 years.
The Finniss Lithium Operation now has an improved mine plan that cuts Grants’ pre-production capital by $35–$45 million and the grants ore reserve has risen by 33% to 1.53 Mt at 1.42% Lithium oxide which boosts contained lithium metal by 44%.

CXO has secured commitments for a $50 million placement plus another $4.3 million from the SPP and ended the September quarter with $35.9 million cash even before the $20.8 million which came from Tranche 2 of the placement by core shareholders on 10 October 2025.
The Termination of the final offtake agreement for Finniss leaves 100% of all future spodumene available for project partners or spot sales.

Integral Diagnostics Limited (ASX: IDX) 

had a good FY25 as it kept growing its clinical network and also got a good boost from the Capitol Health acquisition.
Revenue went up 33.7% to around $628 million mainly because of higher patient numbers, Medicare indexation and operating EBITDA jumped 38.3% to $126.5 million and operating NPAT shot up 74.4% to $31.6 million.

Roughly $7 million of these synergies were realised in FY25 through procurement savings, better workforce alignment and more scale in teleradiology.
Operating EBITDA margin improved to 20.1% and it’s likely to expand more as extra synergies roll in during FY26.

As Investors search for next big growth stories, these ASX small-cap companies are showing breakthrough developments which makes them promising buys right now.

(Source: Company Reports)